Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T2NOW: Dapagliflozin and Saxagliptin in Pediatric T2DM
NCT03199053Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2017
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 23
01
Overview
A Phase 3 trial of dapagliflozin, saxagliptin in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Oct 2017; status: completed.
02
Drugs
dapagliflozinsaxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03199053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03199053.